流式细胞术检测急性髓细胞白血病微小残留病的临床价值

Clinical Value of Flow Cytometry for Minimal Residual Disease of Acute Myeloid Leukemia

目的探讨流式细胞术检测急性髓细胞白血病微小残留病的临床价值。方法采用FCM检测66例初治AML患者诱导化疗前后各亚型髓系抗原阳性表达情况。结果初诊时66例AML患者髓系抗原阳性总表达率为(19.98±11.98)%,M2亚型和髓系抗原MPO阳性表达率最高;诱导化疗结束时46例缓解、20例未缓解。髓系抗原缓解组阳性总表达率为(10.50±10.49)%,未缓解组阳性总表达率为(16.80±17.39)%,2组MPO阳性表达率最高。缓解组与未缓解组患者髓系抗原总阳性表达率均显著高于对照组,差异具有统计学意义(P<0.05);缓解组患者髓系抗原总阳性表达率显著低于未缓解组,差异具有统计学意义(P<0.05)。结论应用9种髓系抗体检测AML患者MRD临床效果满意,能够为指导化疗方案调整和疗效评价提供可靠依据。

Objective To explore the clinical value of flow cytometry for minimal residual disease of acute myeloid leu -kemia.Methods 66 cases of patients with AML ’ s myeloid antigen positive expression were detected by FCM .Results The positive expression rate of myeloid antigen in patients with AML was (19.98 ±11.98)%,and the highest positive expression rate were M2 subtype and medullary system antigen MPO;At the end of the induction chemotherapy ,46 cases had remission ,and 20 cases had no remission.The positive expression rate of myeloid antigen in the remission group was (10.50 ±10.49)%,and the positive expression rate in the non-remission group was (16.80 ±17.39)%.The highest positive expression was MPO .The posi-tive expression rate of medullary system total antigen in the remission group and the non-remission group were higher than that of the control group(P<0.05);The positive expression rate of medullary system total antigen in the remission group were lower than that of the non-remission group(P<0.05).Conclusion Detection of 9 kinds of myeloid antibodies for the patients with AML has good effect ,and it can provide reliable basis for chemotherapy regimens and therapeutic effect .